{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:05:16Z","timestamp":1762898716663},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T00:00:00Z","timestamp":1312502400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>There have been few reports regarding olanzapine (OLZ)\u2010related QT prolongation and hyperprolactinemia. This study evaluated the dose\u2010dependent effect of OLZ on QT interval and plasma prolactin (PRL) level in a single sample of patients with schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010six subjects treated with varying starting doses of OLZ were enrolled in the study. Following baseline assessments, which included completion of the Brief Psychiatric Rating Scale (BPRS), measurements of Body Mass Index (BMI), QT interval, electrolytes, fasting plasma glucose, PRL, hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), and low density lipoprotein (LDL), the dose of OLZ was increased for each subject. The same parameters were evaluated following the increased dose treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A significant decrease was observed in BPRS score (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) following treatment with an increased dose of OLZ. Significant increases were observed in BMI (<jats:italic>p<\/jats:italic>\u2009=\u20090.032), QTc (<jats:italic>p<\/jats:italic>\u2009=\u20090.031), and plasma PRL level (<jats:italic>p<\/jats:italic>\u2009=\u20090.028). The mean values of electrolytes, fasting plasma glucose, HbA1c, TC, TG, HDL and LDL treatment were unchanged by the switch to increased\u2010dose OLZ treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We have demonstrated the dose\u2010dependent effect of OLZ on the QT interval and the plasma PRL level of patients with schizophrenia. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1218","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T13:24:15Z","timestamp":1312550655000},"page":"440-443","source":"Crossref","is-referenced-by-count":23,"title":["Dose\u2010dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia"],"prefix":"10.1002","volume":"26","author":[{"given":"Yutaro","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Sugai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuto","family":"Tsuneyama","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Sawamura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Someya","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences  Niigata Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.44.2.174"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2010.07.002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.11.1774"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2006.00408.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370304800513"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00003"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31817e63a5"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199902000-00011"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.5.1010"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.04.002"},{"key":"e_1_2_8_12_1","first-page":"851","article-title":"Management of psychotropic\u2010induced hyperprolactinemia","volume":"11","author":"Marken PA","year":"1992","journal-title":"Clin Pharm"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.811"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.05.011"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00182-8"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-474X.2001.tb00097.x"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1218","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:38:10Z","timestamp":1695490690000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1002\/hup.1218"],"URL":"https:\/\/doi.org\/10.1002\/hup.1218","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}